{"id":3688,"date":"2018-01-18T17:06:04","date_gmt":"2018-01-18T22:06:04","guid":{"rendered":"http:\/\/www.ipoboutique.com\/blog\/?p=3688"},"modified":"2018-01-19T21:11:47","modified_gmt":"2018-01-20T02:11:47","slug":"eyenovia-inc-ipo-preview-eyen","status":"publish","type":"post","link":"https:\/\/www.ipoboutique.com\/blog\/eyenovia-inc-ipo-preview-eyen\/","title":{"rendered":"Eyenovia Inc #IPO Preview – $EYEN"},"content":{"rendered":"

\"eyenovia\"<\/a><\/p>\n

Company: Eyenovia, Inc.
\nSymbol: EYEN
\nDescription: They are a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing our patented piezo-print technology to deliver micro-doses of active pharmaceutical ingredients, or micro-therapeutics, topically to the eye.
\nShares: 2.73 million
\nPrice Range: $10.00-$12.00
\nTrade Date: TBD
\nUnderwriter(s): Ladenburg Thalmann, Roth Capital Partners
\nTerms Added: 1-9-18<\/p>\n

\"Screen<\/a><\/p>\n

Link to S-1\/A Prospectus<\/a><\/strong><\/p>\n

Link to Retail Roadshow<\/a><\/strong><\/p>\n

Business<\/strong>: Micro-dosing technology has the potential to replace traditional macro-dosing applications (e.g. conventional eye droppers that deliver 30\u201350 \u00b5L) that routinely overdose or under-dose when used in the topical administration of ophthalmic therapeutics. They believe their micro-therapeutic product candidates may be able to achieve similar pharmacologic effects as traditional macro-dosing applications while reducing the adverse effects associated with these techniques. They\u00a0have received written Food and Drug Administration, or FDA, feedback indicating that they\u00a0can proceed to Phase\u00a0III clinical trials for two of their\u00a0lead programs: MicroProst, a novel micro-therapeutic latanoprost formulation for chronic angle closure glaucoma, or CACG, an indication with no FDA-approved drug treatments; and MicroStat, a fixed combination of micro-therapeutic phenylephrine-tropicamide formulation for mydriasis, also known as pupil dilation for use in eye exams. MicroTears, their\u00a0over-the-counter, or OTC, product candidate for dry eye, will not require Phase\u00a0III clinical trials, and they\u00a0plan to proceed with registration activities.<\/p>\n

They have completed two Phase\u00a0II clinical trials, treating more than 110 subjects, with results published in peer-reviewed literature. Applying multiple front-of-the-eye (the area in front of the lens) formulations in subjects for mydriasis, their\u00a0piezo-print technology delivered microliter precision at the volume of the eye\u2019s natural tear film capacity of 6\u20138 \u00b5L, which reduced ocular and systemic drug and preservative exposure when compared to eye drops, resulting in comparable efficacy with fewer side effects. They\u00a0believe that these clinical trials support their\u00a0advancement into late stage clinical trials utilizing the 505(b)(2) pathway. They\u00a0intend to use this pathway for future clinical trials in new indications with significant unmet needs.<\/div>\n
<\/div>\n
Licensing:<\/strong> They have entered into a master licensing partnership for all of their\u00a0micro-therapeutic programs, including their\u00a0MicroStat program, with Senju Pharmaceuticals for Asia, including China, Japan and India.<\/div>\n
<\/div>\n
Insider Buying:<\/strong>\u00a0Certain of their\u00a0existing stockholders and\/or members of management have indicated an interest in purchasing up to an aggregate of\u2009 $5.0 million of shares of their\u00a0common stock in this offering at the public offering price.<\/div>\n
<\/div>\n
Book-Building Status<\/strong>: The way the book comes together during the week of the roadshow is the most critical indicator to first-day and first-week performance. IPO Boutique uses its 45 years of experience and sources all over the street to gather daily subscription levels, specific price guidance and what type of investors are currently in the book or are anchoring orders in the book. In addition, recent underwriter performance on sector specific deals is a strong factor that IPO Boutique takes into account when determining if our clients should indicate for any offering.<\/div>\n

IPO Boutique subscription clients receive daily updates on this critical information.<\/span><\/a><\/p>\n

Conclusion<\/strong>: IPO Boutique provides ratings, daily commentary and a forecast for how this IPO will open vs. its offering price. We have kept a\u00a0track record<\/span><\/a>\u00a0with our performance for last 12 years at our website. Additionally, here’s a 2017 recap of our performance<\/a>\u00a0to showcase the value of IPO Boutique’s service.<\/p>\n

Indicate with confidence,\u00a0<\/b>SUBSCRIBE<\/b><\/a>\u00a0today.<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

Company: Eyenovia, Inc. Symbol: EYEN Description: They are a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing our patented piezo-print technology to deliver micro-doses of active pharmaceutical ingredients, or micro-therapeutics, topically to the eye. Shares: 2.73 million Price Range: $10.00-$12.00 Trade Date: TBD Underwriter(s): Ladenburg Thalmann, Roth Capital Partners Terms Added: 1-9-18[…]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24],"tags":[],"class_list":["post-3688","post","type-post","status-publish","format-standard","hentry","category-ipo"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=3688"}],"version-history":[{"count":2,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3688\/revisions"}],"predecessor-version":[{"id":3741,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/3688\/revisions\/3741"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=3688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=3688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=3688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}